Last reviewed · How we verify
Levocetrizine
Levocetrizine, marketed by Indira Gandhi Medical College, Shimla, is an antihistamine with a well-established presence in the market. The key composition patent for Levocetrizine is set to expire in 2028, providing a significant period of exclusivity and potential revenue protection. The primary risk is the lack of reported key trial results and revenue data, which may limit strategic planning and investor confidence.
At a glance
| Generic name | Levocetrizine |
|---|---|
| Sponsor | Indira Gandhi Medical College, Shimla |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis (PHASE3)
- Steroid Use in Treatment of Allergic Reactions to Food (PHASE4)
- Efficacy of Bilastine Up-dosing (40 mg ) Versus Combination of Bilastine (20 mg )With Levocitirizine (5 mg) in the Treatment of Chronic Spontaneous Urticaria (NA)
- Traditional vs. Posterior Nasal Radiofrequency Ablation for Chronic Rhinitis (NA)
- Parallel, Double-dummy, Superiority Study Levocetirizine/Pseudoephedrine x Zina for Allergic Rhinitis in Brazil (PHASE3)
- COrticosteroids in acUte uRticAria in emerGency dEpartment (PHASE3)
- A Histamine Pharmacodynamic Biomarker to Guide Treatment in Pediatric Asthma (HAS3) (PHASE3)
- A Trial of Camrelizumab Plus Nab-paclitaxel and Levocetirizine in Metastatic or Recurrent TNBC (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Levocetrizine CI brief — competitive landscape report
- Levocetrizine updates RSS · CI watch RSS
- Indira Gandhi Medical College, Shimla portfolio CI